| Exercise-induced bronchoconstriction and asthma. | |
| | |
MedLine Citation:
|
PMID: 20726625 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The objectives are: (1) To assess diagnostic test characteristics of six alternative index tests compared with the selected reference standard-a standardized exercise challenge test (ECT) in patients with suspected exercise-induced bronchoconstriction or asthma (EIB/EIA); (2) to determine the efficacy of a single prophylactic dose of four pharmacologic and one nonpharmacologic interventions vs. placebo to attenuate EIB/EIA in patients with diagnosed EIB/EIA; and (3) to determine if regular daily treatment with short-acting or long-acting beta-agonists (SABA or LABA) causes patients with EIA to develop tachyphylaxis when additional prophylactic doses are used pre-exercise. DATA SOURCES: A systematic and comprehensive literature search was conducted in 14 electronic databases (Diagnosis) and the Cochrane Airways Register (Therapy). REVIEW METHODS: Study selection, quality assessment, and data extraction were conducted independently by two reviewers. The primary outcome was the maximum percent fall in the post-exercise forced expiratory volume in 1 second (percent fall FEV1). The diagnostic threshold for a positive ECT was a percent fall FEV1 of 10% or more. Sensitivity (SN) and specificity (SP) were calculated. For therapy, mean differences (MD) in the percent fall FEV1 and 95% confidence intervals (CI) (random effects model) were calculated. A positive MD indicates the intervention works better than the control. RESULTS: For the diagnostic reviews, 5,318 citations yielded 28 relevant studies; for the therapy reviews, 1,634 citations yielded 109 relevant RCTs. Diagnostic test results versus ECT: self-reported history (2 studies) SN=36-8 percent; SP=85-86 percent; sport specific challenges (5 studies) SN=0-100 percent, SP=0-100 percent; eucapnic voluntary hyperpnea (7 studies) SN=25-90 percent, SP=0-71 percent; free running asthma screening test (3 studies) SN=60-67 percent, SP=47-67 percent; mannitol (3 studies) SN=58-96 percent, SP=65-78 percent. All SN and SP calculations indicated substantial heterogeneity that could not be explained by sensitivity or subgroup analyses. Therapy results: SABA offered greater protection than mast cell stabilizers (MCS) (12 studies); MD=6.8 (95 percent CI: 4.5, 9.2) but combining them offered no additional benefit; SABA versus MCS plus SABA (5 studies) MD=1.3 (95 percent CI: -6.3, 8.9). Leukotriene receptor antagonists (LTRA), MCS, ipratropium bromide, and interval warmup routines provided statistically significant attenuation of EIA when compared with placebo; inhaled corticosteroids (ICS) and other warmup routines did not. Single-dose intervention versus placebo results are: LTRA (9 studies) MD=8.9 (95 percent CI: 6.9, 11.0); MCS (nedocromil sodium) (17 studies) MD=15.6 (95 percent CI: 13.2, 18.2); interval warmup versus no warmup (4 studies) MD=10.6 (95 percent CI: 6.5, 14.7); ICS (4 studies) MD=5.0 (95 percent CI: 0.0, 9.9); continuous low intensity warmup versus no warmup (3 studies) MD=12.6 (95 percent CI: -1.5, 26.7); continuous high intensity warmup versus no warmup (2 studies) MD=9.8 (95 percent CI: -6.4, 26.0). After daily LABA (salmeterol) use for 3 to 4 weeks (4 studies), the percent fall FEV1 following an ECT at 2 and 4 weeks was greater than at day 1 in the LABA arm indicating that tachyphylaxis to prophylactic LABA use occurred. Daily SABA use for 1 week (1 study) also indicated development of tachyphylaxis. However, both LABA and SABA continued to have an attenuating effect on EIA. CONCLUSIONS: Given the small number of studies comparing EIB/EIA diagnostic tests, the heterogeneity of the study populations, and the varied study methodologies, there is no clear evidence that any of the index tests are a suitable replacement for a standardized ECT to diagnose EIB/EIA in the general population. All bronchodilator agents and most anti-inflammatory agents when used as pretreatment are somewhat effective in attenuating the percent fall FEV1 associated with EIA. |
| | |
Authors:
|
Donna M Dryden; Carol H Spooner; Michael K Stickland; Ben Vandermeer; Lisa Tjosvold; Liza Bialy; Kai Wong; Brian H Rowe |
Related Documents
:
|
8442735 - Medullary afferent vagal axotomy disrupts nacl-induced short-term taste aversion learning. 9920215 - Prevalence and characteristics of exercise-induced asthma in children. 4003225 - Airway resistance and lung function in exercise-induced asthma. 6684245 - Complex partial seizures: clinical characteristics and differential diagnosis. 7988205 - The composition of gas given by mouth-to-mouth ventilation during cpr. 1757335 - Absence of exercise-induced mri enhancement of skeletal muscle in mcardle's disease. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Evidence report/technology assessment Volume: - ISSN: 1530-4396 ISO Abbreviation: Evid Rep Technol Assess (Full Rep) Publication Date: 2010 Jan |
Date Detail:
|
Created Date: 2010-08-23 Completed Date: 2010-09-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101082681 Medline TA: Evid Rep Technol Assess (Full Rep) Country: United States |
Other Details:
|
Languages: eng Pagination: 1-154, v-vi Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Agonists
/
therapeutic use* Asthma, Exercise-Induced / diagnosis*, prevention & control Azides / therapeutic use Humans Male Randomized Controlled Trials as Topic Serotonin / analogs & derivatives, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Agonists; 0/Azides; 50-67-9/Serotonin; 98409-42-8/3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Enhancing the use and quality of colorectal cancer screening.
Next Document: Communication: Coalescence of carbon atoms on Cu (111) surface: Emergence of a stable bridging-metal...